WO2004089311A3 - Agents medicamenteux polymeres pour le traitement des affections de type fibrose - Google Patents

Agents medicamenteux polymeres pour le traitement des affections de type fibrose Download PDF

Info

Publication number
WO2004089311A3
WO2004089311A3 PCT/US2004/009919 US2004009919W WO2004089311A3 WO 2004089311 A3 WO2004089311 A3 WO 2004089311A3 US 2004009919 W US2004009919 W US 2004009919W WO 2004089311 A3 WO2004089311 A3 WO 2004089311A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
polymer
fibrotic disorders
polymeric drug
drug agents
Prior art date
Application number
PCT/US2004/009919
Other languages
English (en)
Other versions
WO2004089311A2 (fr
Inventor
James M Pachence
Benjamin A Belinka
Charles L Putnam
Original Assignee
Vectramed Inc
James M Pachence
Benjamin A Belinka
Charles L Putnam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectramed Inc, James M Pachence, Benjamin A Belinka, Charles L Putnam filed Critical Vectramed Inc
Priority to JP2006509537A priority Critical patent/JP2006522140A/ja
Priority to EP04758674A priority patent/EP1608380A2/fr
Priority to CA002521407A priority patent/CA2521407A1/fr
Publication of WO2004089311A2 publication Critical patent/WO2004089311A2/fr
Publication of WO2004089311A3 publication Critical patent/WO2004089311A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention se rapporte à des agents et à des procédés pour traiter les adhérences et les affections de type fibrose, grâce à la libération de médicaments qui retardent ou inhibent la production de tissu fibreux. Un procédé permettant de libérer à partir d'un polymère des agents inhibant les tissus fibreux est décrit. La combinaison polymère/médicament peut être appliquée directement sur la zone affectée, sous la forme d'un liquide, d'un gel ou d'une pâte. Dans une variante, la combinaison polymère/médicament peut être injectée (par injection intraveineuse, intrapéritonéale ou sous-cutanée) dans un excipient approprié.
PCT/US2004/009919 2003-03-31 2004-03-30 Agents medicamenteux polymeres pour le traitement des affections de type fibrose WO2004089311A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006509537A JP2006522140A (ja) 2003-03-31 2004-03-30 線維症の治療用ポリマー薬剤
EP04758674A EP1608380A2 (fr) 2003-03-31 2004-03-30 Agents medicamenteux polymeres pour le traitement des affections de type fibrose
CA002521407A CA2521407A1 (fr) 2003-03-31 2004-03-30 Agents medicamenteux polymeres pour le traitement des affections de type fibrose

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45844903P 2003-03-31 2003-03-31
US60/458,449 2003-03-31
US79013604A 2004-03-02 2004-03-02
US10/790,136 2004-03-02

Publications (2)

Publication Number Publication Date
WO2004089311A2 WO2004089311A2 (fr) 2004-10-21
WO2004089311A3 true WO2004089311A3 (fr) 2004-12-16

Family

ID=33162191

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/009919 WO2004089311A2 (fr) 2003-03-31 2004-03-30 Agents medicamenteux polymeres pour le traitement des affections de type fibrose

Country Status (4)

Country Link
EP (1) EP1608380A2 (fr)
JP (1) JP2006522140A (fr)
CA (1) CA2521407A1 (fr)
WO (1) WO2004089311A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE507845T1 (de) 2003-09-05 2011-05-15 Gen Hospital Corp Polyacetal-arzneimittelkonjugate als freisetzungssystem
US20050106230A1 (en) * 2003-11-17 2005-05-19 Young Janel E. Drug-enhanced adhesion prevention
AU2012200202B2 (en) * 2004-03-10 2013-09-05 Ethicon, Inc. Drug-enhanced adhesion prevention
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
EP2114397A4 (fr) * 2006-12-20 2013-06-12 Medwell Lab Ltd Nouveaux conjugués d'acides gras poly-insaturés avec des amines et utilisations thérapeutiques de ceux-ci
CL2009002167A1 (es) 2008-12-10 2010-10-15 Mersana Therapeutics Inc Formulacion farmaceutica para administracion endovenosa que comprende un compuesto derivado de conjugados de camptotecina-polimero biocompatibles y biodegradables, un agente de estabilizacion, uno o varios tampones y un tensoactivo, util para el tratamiento del cancer.
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
DK2718261T3 (en) * 2011-06-08 2016-03-29 Nitto Denko Corp Compounds to target drug delivery and promote siRNA activity
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372807A (en) * 1990-05-14 1994-12-13 University Of Medicine And Dentistry Of New Jersey Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372807A (en) * 1990-05-14 1994-12-13 University Of Medicine And Dentistry Of New Jersey Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use

Also Published As

Publication number Publication date
CA2521407A1 (fr) 2004-10-21
EP1608380A2 (fr) 2005-12-28
WO2004089311A2 (fr) 2004-10-21
JP2006522140A (ja) 2006-09-28

Similar Documents

Publication Publication Date Title
WO2006036970A3 (fr) Procede permettant d'epaissir un revetement a l'aide d'un medicament
WO2004056311A3 (fr) Systemes reagissant a des stimulis pour l'administration regulee de medicaments
BRPI0513243A (pt) composições oftálmicas e métodos para tratar condições oftálmicas
WO2005115357A3 (fr) Formulations de taurolidine et administration: traitements thérapeutiques et protection antimicrobienne contre la formation de biofilm bactérien
WO2007002572A3 (fr) Nattokinase pour reduire la viscosite du sang total
WO2004071529A3 (fr) Utilisations d'anticorps contre le recepteur de facteur de croissance insulinoide i
WO2006094072A3 (fr) Methode de traitement de troubles cognitifs au moyen d'une neuromodulation
WO2005037323A3 (fr) Methode pour inhiber une signalisation de nf-kappa b et son utilisation pour traiter et pour prevenir des maladies humaines
WO2004087011A3 (fr) Dispositif d'administration d'agents therapeutiques a controle de vitesse de liberation
WO2004072031A8 (fr) Composes d'amides substitues tri(cyclo)
MXPA05013003A (es) Composiciones de deposito elastomerico implantables, usos de las mismas y metodo para elaboracion.
WO2005009408A3 (fr) Formes pharmaceutiques a liberation prolongee d'anesthesiant pour soulager la douleur
WO2006060507A3 (fr) Procedes et compositions d'utilisation de composes immunomodulatoires pour le traitement des troubles d'immunodeficience
EP2182063A3 (fr) Modulation de l'expression EIF4E
WO2007098479A3 (fr) Délivrance localisée d'insuline pour guérison osseuse
WO2004089311A3 (fr) Agents medicamenteux polymeres pour le traitement des affections de type fibrose
WO2004078025A3 (fr) Procedes et dispositif d'assistance vasculaire
WO2006036964A3 (fr) Couche barriere
WO2005105037A3 (fr) Nouvelle utilisation d'une composition visco-elastique
WO2005115493A3 (fr) Traitement thermique de dispositif medical implantable
WO2004010975A3 (fr) Administration regulee de medicaments
WO2006030431A3 (fr) Appareil et methodes de distribution de medicaments biocompatibles
WO2009048384A3 (fr) Dispositif de traitement d'un anévrisme
WO2007105203A3 (fr) Procede et composition pour la protection du tissu neuronal de degats induits par des niveaux eleves de glutamate
WO2008047373A3 (fr) Dispositif et procédé pour l'administration d'un bolus activée par le patient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2521407

Country of ref document: CA

Ref document number: 2006509537

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004758674

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004758674

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004758674

Country of ref document: EP